1. Ahrens M, Scheich S, Hartmann A et al (2019) Oncol Res Treat. https://doi.org/10.1159/000495366
2. Allaf M, Kim SE, Harshman LC et al (2022) Ann Oncol. https://doi.org/10.1016/j.annonc.2022.08.072
3. Alt AL, Boorjian SA, Lohse CM et al (2011) Cancer. https://doi.org/10.1002/cncr.25836
4. https://www.fda.gov/news-events/press-announcements/fda-expands-approval-sutent-reduce-risk-kidney-cancer-returningZugegriffen. Zugegriffen: 14. Dez. 2022
5. Ljungberg B, Bedke J, Bex A, Capitanio U, Giles RH, Hora M, Klatte T, Lam T, Marconi L, Powles T, Volpe A, Guidelines Associates: Abu-Ghanem Y, Dabestani S, Fernández-Pello Montes S, Hofmann F, Kuusk T, Tahbaz R (2022) EAU Guidelines on Renal Cell Carcinoma